Five Prime Therapeutics
Five Prime Therapeutics Newswire

Five Prime Therapeutics Newswire

Comprehensive Real-Time News Feed for Five Prime Therapeutics.

Results 1 - 20 of 70 in Five Prime Therapeutics

  1. Five Prime Announces Oral Presentation Of Initial Data From Ongoing...Read the original story

    Sunday Aug 23 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that initial data from GlaxoSmithKline 's ongoing Phase 1b trial of FP-1039/GSK3052230, an FGF ligand trap, in patients with squamous non small cell lung cancer and mesothelioma will be featured in an oral presentation by study investigators during the upcoming World Conference on Lung Cancer 2015 in Denver .

    Comment?

  2. Recent Analysts' Ratings Changes for Five Prime TherapeuticsRead the original story

    Friday Aug 21 | AmericanBankingNews.com

    A number of firms have modified their ratings and price targets on shares of Five Prime Therapeutics recently: 8/12/2015 - Five Prime Therapeutics had its "outperform" rating reaffirmed by analysts at Oppenheimer. They now have a $45.00 price target on the stock.

    Comment?

  3. Roche buys U.S.-based Kapa BiosystemsRead the original story w/Photo

    Wednesday Aug 19 | MarketWatch

    Roche Holding AG Wednesday said it has bought a U.S. gene-technology company, the latest acquisition in the area by the Swiss pharmaceutical company. Basel-based Roche said it will buy Kapa Biosystems Inc., based in Wilmington, Mass., for an undisclosed sum.

    Comment?

  4. Investment Analysts' Recent Ratings Updates for Five Prime TherapeuticsRead the original story

    Thursday Aug 13 | AmericanBankingNews.com

    They now have a $45.00 price target on the stock. 8/11/2015 - Five Prime Therapeutics was upgraded by analysts at Zacks from a "sell" rating to a "hold" rating.

    Comment?

  5. Roche buys privately-held GeneWEAVE BioSciencesRead the original story w/Photo

    Thursday Aug 13 | MarketWatch

    Roche Holding AG Thursday said it has agreed to buy a U.S. microbiology diagnostic company in a deal which could rise up to $425 million - the latest acquisition in the Swiss pharmaceuticals giant's deeper push into diagnostics. Basel-based Roche said it was buying privately-held GeneWEAVE BioSciences Inc., based in Los Gatos, California, for an initial $190 million and would pay up to $235 million extra depending on the development of products.

    Comment?

  6. Five Prime Therapeutics's Outperform Rating Reaffirmed at OppenheimerRead the original story

    Wednesday Aug 12 | AmericanBankingNews.com

    ... equities research analysts also recently issued research reports about the company. Zacks downgraded Five Prime Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, July 14th. TheStreet lowered Five Prime Therapeutics from a ...

    Comment?

  7. Five Prime Reports Second Quarter 2015 Results And Provides Business UpdateRead the original story

    Thursday Aug 6 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the second quarter ending June 30, 2015. "Five Prime is actively building a comprehensive and complementary portfolio of immuno-oncology candidates and programs that target macrophages, immune check points, T cell agonist pathways and regulatory T cells in the tumor microenvironment," said Lewis T. "Rusty" Williams, M.D., Ph.D., president and chief executive officer of Five Prime.

    Comment?

  8. Five Prime Therapeutics (FPRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSRead the original story

    Thursday Aug 6 | AmericanBankingNews.com

    Five Prime Therapeutics announced its quarterly earnings data on Thursday. The company reported earnings per share for the quarter, missing the analysts' consensus estimate of by $0.01, ARN reports.

    Comment?

  9. bluebird bio Reports Second Quarter 2015 Financial Results and Recent Operational ProgressRead the original story

    Thursday Aug 6 | Freshnews

    ... (TCR) therapies in HPV-associated cancers and entered into an exclusive license agreement with Five Prime Therapeutics around chimeric antigen receptor (CAR) T cell therapies against an undisclosed cancer target for hematologic malignancies and ...

    Comment?

  10. Grabbing slices of the immuno-oncology pieRead the original story w/Photo

    Wednesday Aug 5 | Chemistry World

    Another round of immuno-oncology deals underlines the popularity of harnessing the immune system to attack cancer. Sanofi is partnering Regeneron; Merck & Co is extending its relationship with Ablynx and buying cCAM Biotherapeutics; and Five Prime Therapeutics is licensing technology from Inhibrx.

    Comment?

  11. Five Prime To Announce Second Quarter 2015 Financial Results And Host Conference Call On August 6Read the original story

    Sunday Aug 2 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its second quarter 2015 financial results on Thursday, August 6, 2015 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, August 6 at 5:00 p.m. /2:00 p.m. to discuss the company's financial results and provide a general business update.

    Comment?

  12. Five Prime Therapeutics to Announce Second Quarter 2015 Financial...Read the original story w/Photo

    Friday Jul 31 | GlobeNewswire

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, will report its second quarter 2015 financial results on Thursday, August 6, 2015 after the U.S. financial markets close. Five Prime will host a conference call and live audio webcast on Thursday, August 6 at 5:00 p.m. /2:00 p.m. to discuss the company's financial results and provide a general business update.

    Comment?

  13. Roche gets EU approval for cancer drug PerjetaRead the original story w/Photo

    Friday Jul 31 | MarketWatch

    European regulators approved Roche Holding AG's Perjeta remedy for the pre-surgery treatment of adult patients with breast cancer. Basel-based Roche Friday said the European Commission approved the use of its cancer drug Perjeta, in combination with Herceptin and chemotherapy, for early stage treatment of a type of aggressive breast cancer which carries a high risk of recurrence.

    Comment?

  14. Oncolytics: An Unheralded Biotech With Promising Phase 2 ResultsRead the original story w/Photo

    Jul 28, 2015 | Seeking Alpha

    ... which, if successful, should lead to its first marketable product. Compare this, for example, to Five Prime Therapeutics (NASDAQ: FPRX ) and OncoMed Pharmaceuticals (NASDAQ: OMED ), also developmental-stage cancer biotechs with no Phase II trials ...

    Comment?

  15. Global Antisense and RNAi Therapeutic Market Size, Share, Growth,...Read the original story

    Jul 27, 2015 | PR-inside.com

    Global antisense & RNAi therapeutic market is expected to witness a lucrative growth rate during the forecast period owing to rising prevalence of infectious diseases, and coronary heart disorders which lead to cardiovascular diseases. Incorporation of technologically advanced RNA based technologies such as RNA antisense; RNA nanobiotechnologies, RNA interference, and SMaRT technology are also expected to drive market demand.

    Comment?

  16. Five Prime, Inhibrx Forge $452.5 Million Cancer PactRead the original story

    Jul 15, 2015 | BioSpace

    SOUTH SAN FRANCISCO, Calif., and LA JOLLA, Calif., July 15, 2015 -- Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced a strategic research collaboration and license agreement with Inhibrx for Inhibrx's novel glucocorticoid-induced tumor necrosis factor receptor antibody program, which is currently at lead selection stage. Leveraging its comprehensive protein library and proprietary in vivo screening technologies, Five Prime identified GITR as one of the most potent inhibitors of tumor growth.

    Comment?

  17. Five Prime Initiates Patient Dosing In Phase I/II Clinical Trial...Read the original story

    Jul 12, 2015 | BioSpace

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced that the company has initiated patient dosing in its Phase 1/2 clinical trial of FPA008, a CSF1 receptor antibody, in pigmented villonodular synovitis . "PVNS is characterized by inflammatory tumor growth in and around a joint cavity.

    Comment?

  18. Prenatal DNA test patent invalid, U.S. appeals court saysRead the original story

    Jun 12, 2015 | Reuters

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?

  19. Prenatal DNA Test Patent Invalid, U.S. Appeals Court SaysRead the original story

    Jun 9, 2015 | Medical Daily

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?

  20. UPDATE 1-Prenatal DNA test patent invalid, U.S. appeals court saysRead the original story

    Jun 12, 2015 | Reuters

    A U.S. appeals court said on Friday that the discovery of a new form of prenatal testing that avoids the risks of invasive medical techniques was good for science but did not deserve a patent. The U.S. Court of Appeals for the Federal Circuit in the District of Columbia said a patent held by genetic testing company Sequenom Inc on detecting fetal DNA in a pregnant woman's blood was invalid.

    Comment?